Politicians in Athens will have to show some serious guts to enforce
the austerity measures demanded by its European creditors in the face of a crumbling economy and an angry populace.
Not exact matches
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®;
austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient
demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
Group chairman Paul Rayner used the firm's annual general meeting to warn that
demand for its wines in China was «softening, as a result of the leadership change and well - documented government
austerity measures».
It also said a slowdown in China, where the government has imposed
austerity measures which have curbed
demand for higher - priced wines, had worsened in the past few months.
Hammond had to contend, personally, with the National Insurance U-turn fiasco fresh in everyone's mind from his spring statement as well as, politically, with calls from the Brexiter faction within his own party for a more positive vision, and
demands from the more centrist Tories and the Opposition to relax
austerity measures.
Despite all the progress realized by Samaras» government, Greece's creditors
demanded close to $ 3 billion in new
austerity measures including, among other things, increases in VAT on hotel services up to 13 % (from 6.5 %).
Greeks have witnessed discussions shift from $ 1 billion in additional
measures (last proposal put forth by the New Democracy - PASOK government following
demands from creditors), to over $ 10 billion in additional
measures last month, to today's «Greekment» according to which Greece will undergo harsher
austerity (for next three years) than at any other point since the crisis began.
It should be noted that the
austerity measures she justifies are not intended to contain budget deficit (as in Greece) but to reduce the growth of the prices via reduction of the
demand, that is, by making the population poor intentionally.
Any optimism over preserving the eurozone quickly deflated when industry executives at the Paris auto show last month warned Europe likely will not see improvement for at least the next two years as strict
austerity measures and high unemployment keep the economy weak and stifle consumer
demand.
Greece, like all other countries accepting assistance, was bound to an Economic Adjustment Programme that required
austerity and supply - side reforms, while the new government was elected based on the promise that it would repeal
austerity - driven
measures and focus on
demand - side policies.
The ongoing economic crisis in Greece jumped ferociously back into the world's headlines this summer, when Greek residents voted to reject European
austerity demands and European leaders agreed on a third bailout deal for Greece in exchange for strict reform
measures.